![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1-6 and Human Immunodeficiency Virus-1 Coinfection:
An Integrated Analysis of Two Phase 3 Clinical Trials
|
|
|
Reported by Jules Levin
IDWeek 2018, October 3-7, 2018, San Francisco  
Juergen Rockstroh1, Sanjay Bhagani2, Chloe Orkin3, Ruth Soto-Malave4, Karine Lacombe5, Massimo Puoti 6, Rolando M Viani7, Zhenzhen Zhang7, Stanley Wang7, Federico J Mensa7, Roger Trinh7
1Universitätsklinikum Bonn, Bonn, Germany; 2Royal Free London Foundati on Trust, London, United Kingdom; 3The Royal London Hospital, London, United Kingdom; 4Innovati ve Care P.S.C., Bayamon, Puerto Rico; 5Inserm UMR-S1136, Université Pierre et Marie Curie, Hôpital Saint-Antoine, APHP, Paris, France; 6AO Ospedale Niguarda Ca Granda, Milan, Italy; 7AbbVie Inc., North Chicago, Illinois, United States
![1011181](../images%20/101118/101218-10/1011181.gif)
![1011182](../images%20/101118/101218-10/1011182.gif)
![1011183](../images%20/101118/101218-10/1011183.gif)
![1011184](../images%20/101118/101218-10/1011184.gif)
![1011185](../images%20/101118/101218-10/1011185.gif)
![1011186](../images%20/101118/101218-10/1011186.gif)
![1011187](../images%20/101118/101218-10/1011187.gif)
![1011188](../images%20/101118/101218-10/1011188.gif)
![1011189](../images%20/101118/101218-10/1011189.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|